Printer Friendly

Neurana Pharmaceuticals Touts Results of Study Designed to Confirm the Non-Sedative Effects of Tolperisone, a Novel Skeletal Muscle Relaxant.

M2 PHARMA-October 27, 2017-Neurana Pharmaceuticals Touts Results of Study Designed to Confirm the Non-Sedative Effects of Tolperisone, a Novel Skeletal Muscle Relaxant

(C)2017 M2 COMMUNICATIONS

- US-based specialty pharmaceutical company Neurana Pharmaceuticals Inc has received successful top-line results from a clinical trial designed to confirm the non-sedative effects of tolperisone, the company said.

The Neurana study was designed as a three-way cross-over study in healthy volunteers that included tolperisone, placebo and the leading market-share product in the category, cyclobenzaprine (Flexeril), which has been shown to be sedating in clinical use.

This study used a driving simulation trial design acceptable to the US Food and Drug Administration, and assessed various measures of cognition and sedation including both objective and subjective measures.

The primary endpoint for the study was Standard Deviation of Lateral Position, a driving performance measure that is highly correlated to blood alcohol levels.

On Day 1 at Tmax, tolperisone (450 mg total daily dose) was equivalent to placebo (p=0.9) for the primary endpoint of SDLP, while cyclobenzaprine (30 mg total daily dose) demonstrated significant impairment (p=0.05.

On the morning of Day 2 predose, which assesses the next day residual effects ("hangover"), tolperisone was no different than placebo (p=0.7) for SDLP, while cyclobenzaprine demonstrated significant impairment (p=

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Report
Date:Oct 27, 2017
Words:224
Previous Article:PhaseRx Receives Delisting Notice from NASDAQ, Evaluates Options.
Next Article:Leidos Names Dmitrovsky as President of Leidos Biomedical Research, Laboratory Director of the Frederick National Laboratory for Cancer Research.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters